Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Janux Therapeutics Inc (NASDAQ: JANX) closed at $50.26 in the last session, up 0.12% from day before closing price of $50.20. In other words, the price has increased by $0.12 from its previous closing price. On the day, 0.83 million shares were traded. JANX stock price reached its highest trading level at $51.89 during the session, while it also had its lowest trading level at $49.53.
Ratios:
We take a closer look at JANX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 57.34 and its Current Ratio is at 57.34. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on September 06, 2024, initiated with a Buy rating and assigned the stock a target price of $70.
On May 30, 2024, Scotiabank started tracking the stock assigning a Sector Perform rating and target price of $47.
On March 21, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $62.BTIG Research initiated its Buy rating on March 21, 2024, with a $62 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 13 ’24 when Lichter Jay bought 3,815 shares for $46.68 per share.
Avalon BioVentures I, LP bought 30,613 shares of JANX for $1,438,811 on Sep 12 ’24. On Sep 12 ’24, another insider, Avalon BioVentures SPV I, L.P., who serves as the 10% Owner of the company, bought 161,356 shares for $47.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 2621787648 and an Enterprise Value of 1999199872. For the stock, the TTM Price-to-Sale (P/S) ratio is 173.27 while its Price-to-Book (P/B) ratio in mrq is 3.99. Its current Enterprise Value per Revenue stands at 132.161 whereas that against EBITDA is -31.304.
Stock Price History:
Over the past 52 weeks, JANX has reached a high of $65.60, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is 15.55%, while the 200-Day Moving Average is calculated to be 44.27%.
Shares Statistics:
According to the various share statistics, JANX traded on average about 612.81K shares per day over the past 3-months and 812960 shares per day over the past 10 days. A total of 46.25M shares are outstanding, with a floating share count of 38.62M. Insiders hold about 25.96% of the company’s shares, while institutions hold 80.25% stake in the company. Shares short for JANX as of 1724976000 were 3315464 with a Short Ratio of 5.41, compared to 1722384000 on 3663764. Therefore, it implies a Short% of Shares Outstanding of 3315464 and a Short% of Float of 12.560001000000002.
